TP53 and myeloid neoplasm: In addition, recent methodological advances, such as integrated ‘-omics’ and p53 saturation mutagenesis screens, present new insights into the clinical outcomes in patients with myeloid malignancies, where no evidence of GOF for TP53 missense mutation could be found.